A new dengue vaccine (TAK-003) now WHO recommended in endemic areas; what about travellers?
Journal of Travel Medicine·
- DOI
- 10.1093/jtm/taad132
- PMID
- 37847608
- PMCID
- —
- OpenAlex
- W4387701172
- Study type
- Journal article
- Publisher
- Oxford University Press (OUP)
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The article addresses practical implications of WHO dengue vaccine recommendations for international travelers, providing guidance on vaccine use stratified by prior exposure status. This informs travel medicine practice and pre-travel consultation protocols.
Structured evidence summary
Research question
The article addresses the applicability of the WHO-recommended dengue vaccine TAK-003 (Qdenga) for travelers, distinguishing between those with prior dengue exposure and dengue-naïve individuals.
Study design
This is a commentary or perspective piece published in a peer-reviewed travel medicine journal discussing vaccine policy implications.
Population and setting
The discussion focuses on travelers from dengue non-endemic countries, distinguishing between those with previous travel-related dengue infection and dengue-naïve travelers planning travel to endemic areas.
Main findings
TAK-003 vaccination is identified as beneficial for travelers with prior dengue infection (any serotype) to prevent secondary infection during future travel to dengue-risk areas. For dengue-naïve travelers, the potential benefit is characterized as lower and vaccine use remains discretionary.
Public-health relevance
The article addresses practical implications of WHO dengue vaccine recommendations for international travelers, providing guidance on vaccine use stratified by prior exposure status. This informs travel medicine practice and pre-travel consultation protocols.
Important limitations
This summary is based solely on the supplied single-article abstract and bibliographic metadata. Full interpretation of the vaccine recommendations, supporting evidence, and clinical decision criteria requires review of the complete article.
GIDS interpretation
This article would be discoverable through GIDS topic filters for vaccination and travel medicine, and through the dengue disease classifier. It provides guidance on applying existing WHO vaccine recommendations to specific traveler populations rather than reporting new epidemiological data.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.